

## Patterns of Co-trimoxazole Antibiotic Resistance to Uropathogens in Selected Areas of Dhaka City, Bangladesh

Mohammad Asaduzzaman<sup>1</sup>, Farha Matin Juliana<sup>2</sup>, Azharul Islam Nourin<sup>1</sup>,  
Golam Kibria Hanif<sup>1</sup>, Md. Alamgir Kabir<sup>1</sup>, Md. Jahangir Alam<sup>1</sup>, Nazmul  
Hossain<sup>1</sup>, Biswajit Das<sup>1</sup>, Nazia Rifat Zaman<sup>1</sup>, Lubatul Arabia<sup>1</sup>, Tasneem Ehsan<sup>1</sup>,  
Nayon Al Nahid<sup>3</sup>

<sup>1</sup>Department of Biochemistry, Primeasia University, Banani, Dhaka, Bangladesh

<sup>2</sup>Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh

<sup>3</sup>Department of Biochemistry, Tejgaon College, Dhaka, Bangladesh

\*Corresponding Author: Mohammad Asaduzzaman

---

**Abstract:** The most vital public health problem in developing country like Bangladesh is resistance of different types of antibiotics and their super generations are used irrespectively with different doses in misused and overused forms. Our aim was to assess the susceptible pattern of Co-trimoxazole (Sulfamethoxazole / Trimethoprim) of Sulfonamide antibiotic against uropathogens. A total of 12943 urine samples were collected and out of which 1236 (9.55%) were bacteriologically positive. Among the isolated uropathogens, 95.1% were gram negative and 4.9% gram positive organism. Male were found more prone to get UTI under 10 years and between 51-90 years of age and females were more affected in 10 to 50 years and over 90 years of age group. *E.coli* was the most prevalent (83.9%) isolate followed by *Klebsiella* spp. (6.7%), *Staphylococcus aureus* (2.6%), *Pseudomonas* spp. (2.2%), *Enterococcus* spp. (2.0%) and *Proteus* spp. (1.1%). The most predominant organism *Acinetobacter* spp. and *Enterobacter* spp. (100%) were found sensitive to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) in male patients and *Citrobacter* spp., *Serratia* spp. and *Streptococcus* Group B (100%) in female patients and in male *Enterococcus* spp. (87.5%) and female patients *Acinetobacter* spp. (100%) were found resistant. Around (59.0%) male and (52.6%) female were found resistant to *E. coli*.

**Keywords:** Co-trimoxazole (Sulfamethoxazole / Trimethoprim), Sulfonamides, UTI, Resistance, Uropathogen.

---

Date of Submission: 15-09-2019

Date of acceptance: 03-10-2019

---

### I. Introduction

Antibiotic resistance is an increasing threat to life and morbidity and mortality. Urinary Tract Infection (UTI) is a predominant infection all over the world but it is more prevalent in developing south Asian countries like Bangladesh. Urinary Tract Infection (UTI) represents as one of the most common diseases encountered in medical practices these days and encompasses a broad range of clinical fields that are associated with a common finding of positive urine cultures. Besides every year about 150 million people are affected by UTIs. Worldwide at a cost of about US\$6 billion and even UTIs have demonstrated significant morbidity and mortality.<sup>(1)</sup>

They are the second most common types of infection in humans accounting for 8.3 million doctor's visit annually in USA.<sup>(2)</sup> UTI can be nosocomially ubiquitous in clinical environment so that prevalence rate of uropathogens is being alarmingly accelerated.<sup>(1)</sup> Urinary tract infection is more common in female than male, because of the short length of the urethra and its proximity to anus. Pregnancy and sexual activity also make female more susceptible to UTI. Different factors like age, sex, immunosuppression and urological instruments may affect prevalence of UTIs.<sup>(3)</sup>

The early introduction of effective drugs against bacterial infections in the last century has changed the medical behavior and has significantly reduced the mortality rates due to these agents. Also, the widespread use of antibiotics has induced different mechanisms of bacteria resistance to these drugs.<sup>(4)</sup> Bacterial resistance is naturally developed, being a consequence of bacteria adaptation to the environment. The exposure of microorganisms to different antibiotics increases the selective pressure and favors the development of resistance.<sup>(5)</sup> The etiology of UTIs and the antibiotic susceptibility of urinary pathogens, both in community and hospitals, have been changing over the past years and recently, the antibiotic resistance has become a major global problem.<sup>(6)</sup> A large proportion of uncontrolled antibiotic usage has contributed to the emergence of resistant bacterial infections.<sup>(7)</sup>

However, Co-trimoxazole (Sulfamethoxazole and Trimethoprim) is an antibiotic used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole. It is used for urinary

tract infections. It can be given by mouth or intravenously.<sup>(8)</sup> It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.<sup>(9)</sup> It is available as a generic medication and is not very expensive<sup>(10)</sup>.

Trimethoprim and sulfamethoxazole have a greater effect when given together than when given separately, because they inhibit successive steps in the folate synthesis pathway. They are given in a one-to-five ratio in their tablet formulations so that when they enter the body their concentration in the blood and tissues is roughly one-to-twenty - the exact ratio required for a peak synergistic effect between the two. Sulfamethoxazole, a sulfonamide, induces its therapeutic effects by interfering with the de novo (that is, from within the cell) synthesis of folate inside microbial organisms such as protozoa, fungi and bacteria. It does this by competing with p-aminobenzoic acid (PABA) in the biosynthesis of dihydrofolate. Trimethoprim serves as a competitive inhibitor of dihydrofolate reductase (DHFR), hence inhibiting the de novo synthesis of tetrahydrofolate, the biologically active form of folate.<sup>(11)</sup>

It is the most effective drugs for UTI patients in Bangladesh for treatment of UTI patients. But now a days we see the drugs does not work against uropathogens as before works. Our aim of the study to see the state of susceptibility pattern of Co-trimoxazole (Sulfamethoxazole / Trimethoprim) against Urinary Tract Infection patients in selected areas (Badda, Gulshan, Baridhara, Rampura, Doyagonj, Gandaria, Jatrabari, Sayedabad, Dhaka, Bangladesh).

## II. Materials And Methods

### Materials

**Study Design:** Cross-sectional study.

**Study Location:** This was a retrospective analysis of laboratory data routinely collected from the microbiology department from a Diagnostic Center, Badda, Dhaka-1212 Bangladesh. The total sample volumes were 12943.

### Methods

**Sample Collection and Bacteriological Assessment:** Early morning midstream urine samples were collected aseptically from 12943 (Male-3638 & female-9305) patients. The urine samples were collected into sterile wide container (China) with screw cap tops. On the label were the name, age, sex and time of collection. All the patients were instructed on how to collect the urine samples aseptically and taken to the laboratory immediately for culture. In the diagnostic laboratory, each well mixed urine sample (1µL) was inoculated on MacConkey agar (Oxoid) and Blood agar (Oxoid) media plate under class-II laminar airflow (NUVO Sanaji Malzemelzeni, Imalat Vc Ticaret A.S, Turkey). The inoculum on the plate was streaked out for discrete colonies with a sterile wire loop sterilized by auto loop sterilizer (Germany) following standard procedures. The culture plates were incubated at 37°C by an incubator (Germany) for 48 hours and observed for the growth of bacteria through formation of colonies. All the bacteria were isolated and identified using morphological, microscopy (Japan) and biochemical tests like TSI (HiMedia), MIU (HiMedia) and Simmons Citrate (HiMedia) agar following standard procedures.<sup>(12)</sup>

**Antibiotic Susceptibility Assessment:** The disc diffusion technique was used for antibacterial susceptibility testing of the isolates using commercial antibiotics containing discs. We used the commercial antibiotic disc Ceftriaxone (30µg, Oxoid). Interpretation of results was done using zone sizes. Zones of inhibition for Enterobacteriaceae  $\geq 16$  mm was considered sensitive, 11-15 mm intermediate and  $\leq 10$  mm resistant. Isolates were classified as either sensitive or resistant based on the definition of the Clinical and Laboratory Standard Institute.<sup>(13)</sup> Some laboratory stains of known sensitivity of Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Streptococcus pneumoniae ATCC 49619 were used as quality control strains for the antimicrobial discs.

**Statistical Analysis:** Data were assessed using the Statistical Package for Social Science (IBM SPSS Statistics, version 18, IBM Corporation, SPSS Inc. Chicago, III, USA).

## III. Results

The total 12943 urine samples collected from patients, 1236 (9.55%) samples were positive and 11707 (90.45%) samples were negative in selected areas (Badda, Gulshan, Baridhara, Rampura, Doyagonj, Gandaria, Jatrabari, Sayedabad, Dhaka, Bangladesh).

**Table-1: Distribution table of Urinary Tract Infection (UTI) patients by age groups and gender (n=1236)**

Age (Years)	<10	11-20	21-30	31-40	41-50	51-60	61-70	71-80	81-90	>90
Male	53	05	19	16	26	38	73	38	05	02
Female	103	83	181	113	149	130	124	56	14	08
Total	156	88	200	129	175	168	197	94	19	10

In our study, table-1 showed the distribution table of urinary tract infection affected patients by their age groups and gender. The highest of the study subjects under goes to the 21-30 years age group (200 patients=181 female + 19 male) and followed by 61-70 years age group (197 patients=124 female + 73 male), 41-50 years age group (175 patients=149 female + 26 male), 51-60 years age group (168 patients= 130 females + 38 males) and <10 years age group (156 patients= 103 females + 53 males) respectively. Most prevalent frequency of female and male patients affected by uropathogens was found in 21-30 years and 61-70 years age group respectively.




Figure-1: UTI percentage among different age groups of male (N=275) and female (N=961).

The percentage of male patients were more than female patients (19.3% > 10.7%) under 10 years age groups. In between 11-20, 21-30, 31-40 and 41-50 years of age group female UTI infection (8.6%, 18.8%, 11.8% and 15.5% respectively) is higher than male (1.8%, 6.9%, 5.8% and 9.5% respectively). In between 51-60, 61-70, 71-80 and 81-90 years age male infection (13.8%, 26.5%, 13.8% and 1.8% respectively) is higher than female (13.5%, 12.9%, 5.8% and 1.5% respectively). Above 90 years age female infection (0.8%) is higher than male (0.7%) but here number of patients were very few.

Table-2: Distribution of specific uropathogen mediated UTI among UTI patients

Organisms	Percentage (n=1236)		
	Male	Female	Total
E. coli	222(18.0%)	815(65.9%)	1037(83.9%)
Klebsiella spp.	17(1.4%)	66(5.3%)	83(6.7%)
Staphylococcus aureus	5(0.4%)	27(2.2%)	32(2.6%)
Pseudomonas spp.	15(1.2%)	12(1.0%)	27(2.2%)
Enterococcus spp.	8(0.6%)	17(1.4%)	25(2.0%)
Proteus spp.	6(0.5%)	8(0.6%)	14(1.1%)
Enterobacter spp.	1(0.1%)	9(0.7%)	10(0.8%)
Acinetobacter spp.	1(0.1%)	1(0.1%)	2(0.2%)
Serratia spp.	0(0.0%)	2(0.2%)	2(0.2%)
Staphylococcus saprophyticus	0(0.0%)	2(0.2%)	2(0.2%)
Citrobacter spp.	0(0.0%)	1(0.1%)	1(0.1%)
Streptococcus Group B	0(0.0%)	1(0.1%)	1(0.1%)
Total	275(22.2%)	961(77.8%)	1236(100.0%)

Table 2 showed that the most predominant organism E. coli 1037(male 222 and female 815) found in UTI patients. According to number or percentage distribution, the second prevalent organism was Klebsiella spp. 83 (male 17 & female 66) followed by Staphylococcus aureus 32 (male 5 and female 27), Pseudomonas spp. 27 (male 15 and female 12), Enterococcus spp. 25 (male 8 and female 17), Proteus spp. 14 (male 6 and female 8) and Enterobacter spp. 10 (male 1 and female 9) respectively. In total bacteriologically positive cases, the most prone organism in male and female were E. coli (18.0% and 65.9 %) respectively. Moreover, all the isolated organisms were found highest in female except Pseudomonas spp. in contrast male patients. On the other hand the study showed that the total 22.2% male patients and 77.8% female patients were found.

**Table-3: Prevalence of different uropathogens among male and female patients.**

Organisms	Male (n=275)		Female (n=961)	
	Number	Percentage	Number	Percentage
E. coli	222	80.7%	815	84.8%
Klebsiella spp.	17	6.2%	66	6.9%
Staphylococcus aureus	5	1.8%	27	2.8%
Pseudomonas spp.	15	5.5%	12	1.2%
Enterococcus spp.	8	2.9%	17	1.8%
Enterobacter spp.	1	0.4%	9	0.9%
Proteus spp.	6	2.2%	8	0.8%
Serratia spp.	0	0.0%	2	0.2%
Staphylococcus saprophyticus	0	0.0%	2	0.2%
Acinetobacter spp.	1	0.4%	1	0.1%
Citrobacter spp.	0	0.0%	1	0.1%
Streptococcus Group B	0	0.0%	1	0.1%
Total	275	100.0%	961	100.0%

In this study, the urinary tract infections of female patients (961) were more prone to male patients (275). In male, the most predominant uropathogen were E.coli (80.7%) followed by Klebsiella spp. (6.2%), Pseudomonas spp. (5.5%), Enterococcus spp. (2.9%), Staphylococcus aureus (1.8%). In female, the most prevalent uropathogen were E.coli (84.8%) followed by Klebsiella spp. (6.9%), Staphylococcus aureus (2.8%), Enterococcus spp. (1.8%), Pseudomonas spp. (1.2%). The study noted that female patients were more infected by all of the isolated organism (E. coli, Klebsiella spp., Staphylococcus aureus, Enterobacter spp, Serratia spp., Staphylococcus saprophyticus, Citrobacter spp. and Streptococcus Group B) except some organisms (Pseudomonas spp. and Enterococcus spp., Proteus spp. and Acinetobacter spp.) but here the number were very few.

**Table-4: Susceptibility pattern of Co-trimoxazole (Sulfamethoxazole and Trimethoprim), against uropathogens among male UTI patients (n=275)**

Name of organisms	Sensitive		Resistant	
	Number	Percentage	Number	Percentage
E. coli	91	41.0%	131	59.0%
Proteus spp.	2	33.3%	4	66.7%
Pseudomonas spp.	5	33.3%	10	66.7%
Klebsiella spp.	5	29.4%	12	70.6%
Enterobacter spp.	1	100.0%	0	0.0%
Staphylococcus aureus	2	40.0%	3	60.0%
Enterococcus spp.	1	12.5%	7	87.5%
Acinetobacter spp.	1	100.0%	0	0.0%
Total	108	39.3%	167	60.7%

Table-4 showed that Co-trimoxazole (Sulfamethoxazole / Trimethoprim) sensitive against isolated uropathogenic bacteria in total male patients were 39.3% and rest are resistant 60.7%. All of them (100%) Acinetobacter spp. and Enterobacter spp. were sensitive to Co-trimoxazole (Sulfamethoxazole and Trimethoprim) but here the numbers were very few. On the other hand the most prevalent resistant organism was Enterococcus spp. (87.5%). In contrast of frequency, E. coli was the most significant organism which was 41.0 % sensitive and 59.0 % resistant to Co-trimoxazole (Sulfamethoxazole / Trimethoprim). However, the other isolated bacteria's sensitive pattern to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) followed by Proteus spp.( 33.3%), Pseudomonas spp. (33.3%), Klebsiella spp. (29.4%), Staphylococcus aureus (40.0%) and Enterococcus spp. (12.5%) and resistant pattern followed by Proteus spp.( 66.7%), Pseudomonas spp. (66.7%), Klebsiella spp. (70.6%) and Staphylococcus aureus (60.0%) respectively.

**Table-5: Susceptibility pattern of Co-trimoxazole (Sulfamethoxazole / Trimethoprim) against uropathogens among female UTI patients (n=961)**

Name of organisms	Sensitive		Resistant	
	Number	Percentage	Number	Percentage
E. coli	386	47.4%	429	52.6%
Proteus spp.	2	25.0%	6	75.0%
Pseudomonas spp.	2	16.7%	10	83.3%
Klebsiella spp.	35	53.0%	31	47.0%
Enterobacter spp.	5	55.6%	4	44.4%
Staphylococcus aureus	11	40.7%	16	59.3%
Enterococcus spp.	3	17.6%	14	82.4%
Acinetobacter spp.	0	0.0%	1	100.0%
Citrobacter spp.	1	100.0%	0	0.0%
Streptococcus Group B	1	100.0%	0	0.0%
Serratia spp.	2	100.0%	0	0.0%
Staphylococcus saprophyticus	1	50.0%	1	50.0%
Total	449	46.7%	512	53.3%

In our study table-5 showed that Co-trimoxazole (Sulfamethoxazole / Trimethoprim) sensitive against isolated uropathogenic bacteria in total female patients were 46.7% and rest of resistant 53.3%. All of them (100%) Citrobacter spp., Staphylococcus saprophyticus Serratia spp. were sensitive to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) but here the numbers were very few. On the other hand the most prevalent resistant organism was Acinetobacter spp. (100%) but here the numbers were very few. By contrast of frequency, E.coli was the most significant organism which was 47.4% sensitive and 52.6% resistant to Co-trimoxazole (Sulfamethoxazole / Trimethoprim). However, the other isolated bacteria's sensitive pattern to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) followed by Proteus spp. ( 25.0%), Pseudomonas spp. (16.7%), Klebsiella spp. (53.0%), Enterobacter spp. (55.6%), Staphylococcus aureus (40.7%), Enterococcus spp. (17.6%) and Staphylococcus saprophyticus (50.0%) and resistant pattern followed by Proteus spp.( 75.0%), Pseudomonas spp. (83.3%), Klebsiella spp. (47.0%), Enterobacter spp. (44.4%), Staphylococcus aureus (59.3%), Enterococcus spp. (82.4%) and Staphylococcus saprophyticus (50.0%) respectively.

#### IV. Discussion

For misuse or abuse of antibiotics, followed by an increase in the bacterial resistance rates, this study aimed to evaluate the pattern of antimicrobial susceptibility of bacteria isolated from patients with UTI seen at the IBN SINA diagnostic center, Badda, Dhaka, Bangladesh. Moreover, we have identified the crucial bacterial species associated with UTI and described the profile of resistance to Co-trimoxazole (Sulfamethoxazole and Trimethoprim). It is important that clinicians are aware of the regional antibiotic resistance rates before initiating experimental antimicrobial therapy for UTI treatment, as it is well-described that urinary infection with a resistant pathogen is more likely to lead to bacteriological/clinical failures.<sup>(14)</sup> In our study, we tested total 12943 urine samples and 1236 (9.55%) were bacteriological positive and 11707 (90.45%) were bacteriological negative found.

In our study we found The highest of the study subjects under goes to the 21-30 years age group (200 patients=181 female + 19 male) and followed by 61-70 years age group (197 patients=124 female + 73 male), 41-50 years age group (175 patients=149 female + 26 male), 51-60 years age group (168 patients= 130 females + 38 males) and <10 years age group (156 patients= 103 females + 53 males) respectively. According to frequency in total infected patients, we saw that mostly female patients are affected by uropathogens in all the age groups in contrast male patients. It was noted that the highest frequency of UTIs observed in women when compared to men, which is often attributed to a shorter urethra that facilitates colonization by these microorganisms.<sup>(1)</sup> Most prevalent frequency of female and male patients affected by uropathogens was found in 21-30 years and 61-70 years age group respectively. However, there were found significant difference between the age groups and sex of urinary tract infection patients at 5% (P<0.05).

In the figure we saw the percentage of male patients were more porne in contrast female patients (19.3% > 10.7%) under 10 years age groups. Our finding is supported by the fact that uncircumcised male infants appear to be at increased risk of UTIs in the first three months of life. In a study of 100 otherwise healthy infants ranging in age from five days to eight months and admitted to the hospital because of a first known UTI. Most of the UTIs in infants younger than three months of age were in males, but female infants predominated thereafter.<sup>(15)</sup> We also found in between 11-20, 21-30, 31-40 and 41-50 years of age group female UTI infection (8.6%, 18.8%, 11.8% and 15.5% respectively) is higher than male (1.8%, 6.9%, 5.8% and 9.5% respectively). In between 51-60, 61-70 , 71-80 and 81-90 years age male infection (13.8%, 26.5%, 13.8% and 1.8% respectively) is higher than female (13.5%, 12.9%, 5.8 % and 1.5% respectively). Above 90 years age female infection (0.8%) is higher than male (0.7%) but here number of patients were very few. The most predominant



age group was 21-20 years in female patients. Incidence of infection in females increases directly with sexual activity and child-bearing. In the women, 25-30% of women between 20-40 years of age will get UTIs. The anatomical relationship of the female urethra and the vagina makes it liable to trauma during sexual intercourse as well as bacteria being massaged up the urethra into the bladder during pregnancy and child birth. It has been reported in several studies that women who are sexually active, and especially if they use contraceptives, foams, gels, diaphragm and spermicides which are known to promote greater colonization of the vagina are at higher risk of developing UTIs.<sup>(1)</sup> Furthermore, another mechanism that could explain the lower frequency of UTI in men would be the prostatic fluid, which has antibacterial substances.<sup>(16)</sup> We got 961 (77.8%) female and 275 (22.2%) male patients. However, there was found significant difference between the percentage of age groups and sex of urinary tract infection patients at 5% ( $P < 0.05$ ).

Table 2 showed that the most predominant organism *E. coli* 1037 (male 222 and female 815) found in UTI patients. According to number or percentage distribution, the second prevalent organism was *Klebsiella* spp. 83 (male 17 & female 66) followed by *Staphylococcus aureus* 32 (male 5 and female 27), *Pseudomonas* spp. 27 (male 15 and female 12), *Enterococcus* spp. 25 (male 8 and female 17), *Proteus* spp. 14 (male 6 and female 8) and *Enterobacter* spp. 10 (male 1 and female 9) respectively. In total bacteriologically positive cases, the most prone organism in male and female were *E. coli* (18.0% and 65.9 %) respectively. There is fecal contamination of periurethral area, then the bacteria spreads on ascending through the bladder and causes cystitis. These infections of the lower urinary tract, in some cases, can affect the kidneys and cause acute pyelonephritis, which consequently may result in bacteremia and sepsis.<sup>(17)</sup> Moreover, all the isolated organisms were found highest in female except *Pseudomonas* spp. in contrast male patients. On the other hand the study showed that the total 22.2% male patients and 77.8% female patients were found. Moreover, there was found significant difference between the isolated organism and sex of urinary tract infection patients at 5% ( $P < 0.05$ ). In this study, the urinary tract infections of female patients (961) were more prone to male patients (275). In male, the most predominant uropathogens were *E. coli* (80.7%) followed by *Klebsiella* spp. (6.2%), *Pseudomonas* spp. (5.5%), *Enterococcus* spp. (2.9%), *Staphylococcus aureus* (1.8%). In female, the most prevalent uropathogen was *E. coli* (84.8%) followed by *Klebsiella* spp. (6.9%), *Staphylococcus aureus* (2.8%), *Enterococcus* spp. (1.8%), *Pseudomonas* spp. (1.2%). Several studies have shown that *Escherichia coli* is the major bacterial species associated with UTIs, and *Klebsiella pneumoniae* is the second most important bacteria in this type of infection<sup>(18)</sup>. The study noted that female patients were more infected by all of the isolated organisms (*E. coli*, *Klebsiella* spp., *Staphylococcus aureus*, *Enterobacter* spp., *Serratia* spp., *Staphylococcus saprophyticus*, *Citrobacter* spp. and *Streptococcus* Group B) except some organisms (*Pseudomonas* spp. and *Enterococcus* spp., *Proteus* spp. and *Acinetobacter* spp.) but here the number were very few. However, there was found significant difference between the percentage and frequency of isolated organism and sex of urinary tract infection patients at 5% ( $P < 0.05$ ).

Treatment of urinary tract infections is becoming more complicated with an increase of the number of resistant strains to antibiotics and prevalence of antibiotic resistance mechanisms. Table-4 showed that Co-trimoxazole (Sulfamethoxazole / Trimethoprim) sensitive against isolated uropathogenic bacteria in total male patients were 39.3% and rest of resistant 60.7%. All of them (100%) *Acinetobacter* spp. and *Enterobacter* spp. were sensitive to Co-trimoxazole (Sulfamethoxazole and Trimethoprim) but here the numbers were very few. On the other hand the most prevalent resistant organism was *Enterococcus* spp. (87.5%). In contrast of frequency, *E. coli* was the most significant organism which was 41.0 % sensitive and 59.0 % resistant to Co-trimoxazole (Sulfamethoxazole / Trimethoprim). However, the other isolated bacteria's sensitive pattern to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) followed by *Proteus* spp. (33.3%), *Pseudomonas* spp. (33.3%), *Klebsiella* spp. (29.4%), *Staphylococcus aureus* (40.0%) and *Enterococcus* spp. (12.5%) and resistant pattern followed by *Proteus* spp. (66.7%), *Pseudomonas* spp. (66.7%), *Klebsiella* spp. (70.6%) and *Staphylococcus aureus* (60.0%) respectively. There was no significant difference among the susceptibility pattern of Co-trimoxazole (Sulfamethoxazole / Trimethoprim), isolated organism and sex of the patients at 5% ( $P > 0.05$ ).

In our study table-5 showed that Co-trimoxazole (Sulfamethoxazole / Trimethoprim) sensitive against isolated uropathogenic bacteria in total female patients were 46.7% and rest of resistant 53.3%. All of them (100%) *Citrobacter* spp., *Staphylococcus saprophyticus* *Serratia* spp. were sensitive to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) but here the numbers were very few. On the other hand the most prevalent resistant organism was *Acinetobacter* spp. (100%) but here the numbers were very few. By contrast of frequency, *E. coli* was the most significant organism which was 47.4% sensitive and 52.6% resistant to Co-trimoxazole (Sulfamethoxazole / Trimethoprim). However, the other isolated bacteria's sensitive pattern to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) followed by *Proteus* spp. (25.0%), *Pseudomonas* spp. (16.7%), *Klebsiella* spp. (53.0%), *Enterobacter* spp. (55.6%), *Staphylococcus aureus* (40.7%), *Enterococcus* spp. (17.6%) and *Staphylococcus saprophyticus* (50.0%) and resistant pattern followed by *Proteus* spp. (75.0%), *Pseudomonas* spp. (83.3%), *Klebsiella* spp. (47.0%), *Enterobacter* spp. (44.4%), *Staphylococcus aureus* (59.3%), *Enterococcus* spp. (82.4%) and *Staphylococcus saprophyticus* (50.0%) respectively. There were no

significant difference among the susceptibility pattern of Co-trimoxazole (Sulfamethoxazole / Trimethoprim), isolated organism and sex of the patients at 5% ( $P > 0.05$ ).

The knowledge on the regional pattern of bacterial resistance is critical to guide the medical staff to choose an appropriate antibiotic for the treatment of UTI patients.<sup>(19)</sup> Bacterial resistance has become a public health issue and has increasingly been associated with risk factors that put life in danger.<sup>(1)</sup> Awareness is needed of both the population and health professionals about the importance for the correct use of antibiotics, and it is mandatory to take into account the result of antibiotics susceptibility tests. The Co-trimoxazole (Sulfamethoxazole / Trimethoprim) use should be performed only after the microbial susceptibility confirmation, and it is necessary to find other alternatives for the empirical treatment. The bacterial resistance prevention can be performed through control measures that limit the spread of resistant bacteria and the rational use of antimicrobial policy.

## V. Conclusion

In a nutshell, the results showed that there was a high prevalence of occurrence of urinary tract infection among patients of areas (Badda, Gulshan, Baridhara, Rampura, Doyagonj, Gandaria, Jatrabari, Sayedabad, Dhaka, Bangladesh). Most of the bacteria were resistant to Co-trimoxazole (Sulfamethoxazole / Trimethoprim) which is an alarming message for humanity. It is recommended to prescribe Co-trimoxazole (Sulfamethoxazole / Trimethoprim) antibiotic to follow the antibiotic guidelines in order to prevent emergence of multi drug resistant organisms.

## Reference

- [1]. Jahangir Alam, Farha Matin Juliana, Md Rahimgir, Mohammad Nazir Hossain, Babry Fatema, Mohammad Asaduzzaman. "Resistance Pattern of Ciprofloxacin against common Uropathogens in Selected Area of Dhaka city, Bangladesh." IOSR Journal of Nursing and Health Science (IOSR-JHNS), vol. 6, no. 5, 2017, pp. 52-57.
- [2]. Annabelle TD, Jennifer AC. Surveillance of pathogens and resistance patterns in urinary tract infection. *Phil J Microbial Infect Dis* 1999;28:11-4.
- [3]. Iqbal T, Naqvi R, Akhter SF. (2010). Frequency of urinary tract infection in renal transplant recipients and effect on graft function. *J Pak Med Assoc.* 60(10):826-829.
- [4]. Silveira GP, Nome F, Gesser JC, Sá MM, Terenzi H (2006). Estratégias utilizadas no combate a resistência bacteriana. *Quím Nova.* 29:844-55.
- [5]. Santos NQ (2004). A resistência bacteriana no contexto da infecção hospitalar. *Texto Contexto Enferm.* 13:64-70.
- [6]. Savita Jadhav, Arif Hussain, Savita Devi, Ashutosh Kumar, Sana Parveen, Nageshwari Gandham, Lothar H. Wieler, Christa Ewers, and Niyaz Ahmed (2011). Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic *Escherichia coli* from a semi urban locality in India. *PLoS One.* 6(3):ee18063.
- [7]. Grude N, Tveten Y, Kristiansen BE (2001). Urinary tract infections in Norway: bacterial etiology and susceptibility, a retrospective study of clinical isolates. *Clin Microbiol Infect* 2001;7:543-547.
- [8]. "Co-trimoxazole". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-06. Retrieved Aug 1, 2015.
- [9]. "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- [10]. Hamilton, Richard (2015). *Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition*. Jones & Bartlett Learning. p. 105. ISBN 9781284057560.
- [11]. Wormser, GP; Keusch, GT; Heel, RC (December 1982). "Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy". *Drugs.* 24 (6): 459–518. doi:10.2165/00003495-198224060-00002. PMID 6759092.
- [12]. Cheesborough M (2006). *District Laboratory practice in Tropical Countries*, Cambridge United Press, UK, part 2 .pp 7-106.
- [13]. Clinical and Laboratory Standard Institute (2006). *Methods for the Dilution Antimicrobial Susceptibility Tests for Bacteria. That Grow Aerobically. Approved Standards, Seventh Edition (M07)*, Villanova pp. MO 7-A 7.
- [14]. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnowski B, Johnson J, Noreddin A, Don E, Low DE, Karlowksy JA, Hoban DJ (2006). Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int J Antimicrob Agents.* 2006;27(6):468-75.
- [15]. Ginsburg CM, McCracken GH Jr (1982). Urinary tract infections in young infants. *Pediatrics.* 69:409–12.
- [16]. Soares LA, Nishi CY, Wagner HL (2006). Isolamento das bactérias causadoras de infecções urinárias e seu perfil de resistência aos antimicrobianos. *Rev Bras Med Fam Com.* 2:84-92.
- [17]. Mobley H (2016). Measuring *Escherichia coli* Gene Expression during Human Urinary Tract Infections. *Pathogens.* 2016;5(1):7.
- [18]. Ako-Nai AK, Adeyemi FM, Aboderin OA, Kassim OO (2005). Antibiotic resistance profile of staphylococci from clinical sources recovered from infants. *Afr. J. Biotechnol.* 4(8):816-822.
- [19]. The knowledge on the regional pattern of bacterial resistance is critical to guide the medical staff to choose an appropriate antibiotic for the treatment of UTI patients.

Mohammad Asaduzzaman" Patterns of Co-trimoxazole Antibiotic Resistance to Uropathogens in Selected Areas of Dhaka City, Bangladesh" *International Journal of Engineering Science Invention (IJESI)*, Vol. 08, No., 2019, PP 61-67